A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Clinical trial NCT03125395 · COMPLETED
Trial details
- NCT number
- NCT03125395
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-05-12
- Primary completion
- 2019-07-17
- Enrollment
- 57
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.